

VIA FACSIMILE TRANSMISSION  
Date of Deposit: January 16, 2002

Attorney Docket No. 22058-521

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Keith et al.

SERIAL NUMBER: 09/521,696

EXAMINER: J. Seharaseyon

FILING DATE: March 9, 2000

ART UNIT: 1647

FOR: Use of Interleukin-11 To Prevent Immune-Mediated Cytotoxicity

Assistant Commissioner for Patents  
Washington, D.C. 20231

**SUPPLEMENTAL RESPONSE**

Further to the Amendment submitted November 26, 2001 for the above-referenced application, applicants submit herewith a clean copy of the claim amendments and new claims added.

*B1* 1. (Amended) A method of preventing complement-mediated cytotoxicity in a mammal

which comprises

*Sub C1* identifying a mammal at risk of developing complement-mediated cytotoxicity; and administering to said mammal, prior to tissue transplantation, a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 prevents complement-mediated cytotoxicity in said mammal

*B2* 3. (Amended) A method of ameliorating complement-mediated cytotoxicity in a

mammal which comprises

*Sub C2* identifying a mammal at risk of developing complement-mediated cytotoxicity; and